Fresenius Medical Care, a leading global provider of products and services for individuals with renal diseases, is headquartered in the United States. Founded in 1996, the company has established a strong presence in North America, Europe, and Asia, focusing on dialysis services and the manufacture of dialysis equipment. With a commitment to innovation, Fresenius Medical Care offers a comprehensive range of products, including dialysis machines and consumables, which are distinguished by their advanced technology and patient-centric design. The company is recognised for its significant market position, serving millions of patients worldwide and achieving notable milestones in improving patient outcomes. As a key player in the healthcare industry, Fresenius Medical Care continues to lead in the development of integrated care solutions, enhancing the quality of life for those affected by chronic kidney disease.
How does Fresenius Medical Care's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fresenius Medical Care's score of 64 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Fresenius Medical Care reported total carbon emissions of approximately 3,680,827,000 kg CO2e. This figure includes 387,049,000 kg CO2e from Scope 1 emissions, which primarily arise from direct operations, and 466,600,000 kg CO2e from Scope 2 emissions, related to purchased electricity and heat. Additionally, Scope 3 emissions accounted for about 3,958,000,000 kg CO2e, encompassing indirect emissions from the supply chain and product use. Fresenius Medical Care has committed to achieving net-zero emissions across all scopes by 2050, as part of its long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which the company joined in 2024. The company has set a baseline year of 2023 for its emissions reduction efforts, although specific percentage reduction targets have not been disclosed. Over the years, the company has seen fluctuations in its emissions, with Scope 1 emissions increasing from 218,700,000 kg CO2e in 2018 to 387,049,000 kg CO2e in 2023. Scope 2 emissions also varied, peaking at 557,200,000 kg CO2e in 2018 before decreasing to 466,600,000 kg CO2e in 2023. The company has disclosed emissions data for all three scopes, demonstrating transparency in its environmental impact reporting. Fresenius Medical Care's ongoing commitment to sustainability and climate action reflects its recognition of the healthcare sector's role in addressing climate change, aiming to reduce its carbon footprint while continuing to provide essential healthcare services.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Scope 1 | 218,700,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Medical Care is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.